Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $93000.0.

  • Karyopharm Therapeutics' Other Working Capital Changes rose 10494.68% to $93000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.1 million, marking a year-over-year decrease of 49183.29%. This contributed to the annual value of -$4.1 million for FY2025, which is 49183.29% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Other Working Capital Changes of $93000.0 as of Q4 2025, which was up 10494.68% from -$223000.0 recorded in Q3 2025.
  • Karyopharm Therapeutics' Other Working Capital Changes' 5-year high stood at $21.8 million during Q4 2021, with a 5-year trough of -$6.9 million in Q3 2022.
  • Its 5-year average for Other Working Capital Changes is $1.0 million, with a median of -$652500.0 in 2022.
  • In the last 5 years, Karyopharm Therapeutics' Other Working Capital Changes soared by 352105.26% in 2022 and then tumbled by 26035.4% in 2025.
  • Quarter analysis of 5 years shows Karyopharm Therapeutics' Other Working Capital Changes stood at $21.8 million in 2021, then plummeted by 110.08% to -$2.2 million in 2022, then soared by 51.62% to -$1.1 million in 2023, then crashed by 77.02% to -$1.9 million in 2024, then skyrocketed by 104.95% to $93000.0 in 2025.
  • Its Other Working Capital Changes stands at $93000.0 for Q4 2025, versus -$223000.0 for Q3 2025 and -$2.0 million for Q2 2025.